MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give MeiraGTx a consensus "Moderate Buy" rating (1 sell, 1 hold, 4 buy, 1 strong buy) with an average 12‑month price target of $26.00.
• Institutional investors own about 67.48% of the shares, with recent buying including Invesco increasing to 90,881 shares and Opaleye initiating a ~$3.1M position.
• Shares trade around $7.39 (1‑year range $4.55–$9.73) with a market cap of roughly $595M, a negative P/E (‑3.50) and very low current/quick ratios (0.22), indicating profitability and liquidity challenges.

Shares of MeiraGTx Holdings PLC (NASDAQ:MGTX - Get Free Report) have received an average rating of "Moderate Buy" from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $26.00.

A number of brokerages recently commented on MGTX. Weiss Ratings reiterated a "sell (d-)" rating on shares of MeiraGTx in a research note on Thursday, January 22nd. Zacks Research upgraded shares of MeiraGTx from a "strong sell" rating to a "hold" rating in a research report on Monday, March 9th. Finally, HC Wainwright assumed coverage on MeiraGTx in a report on Monday, November 24th. They set a "buy" rating and a $20.00 price objective for the company.

Institutional Trading of MeiraGTx

Several institutional investors have recently added to or reduced their stakes in MGTX. Invesco Ltd. grew its holdings in MeiraGTx by 30.8% in the 4th quarter. Invesco Ltd. now owns 90,881 shares of the company's stock valued at $723,000 after buying an additional 21,381 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of MeiraGTx by 11.0% during the fourth quarter. XTX Topco Ltd now owns 38,030 shares of the company's stock worth $302,000 after buying an additional 3,766 shares in the last quarter. VARCOV Co. bought a new stake in shares of MeiraGTx in the fourth quarter valued at about $262,000. Virtus Investment Advisers LLC acquired a new position in shares of MeiraGTx in the fourth quarter valued at about $237,000. Finally, Opaleye Management Inc. acquired a new position in shares of MeiraGTx in the fourth quarter valued at about $3,107,000. 67.48% of the stock is currently owned by institutional investors.

MeiraGTx Price Performance

NASDAQ:MGTX opened at $7.39 on Monday. MeiraGTx has a one year low of $4.55 and a one year high of $9.73. The company has a market cap of $594.82 million, a P/E ratio of -3.50 and a beta of 1.37. The firm's fifty day moving average price is $7.57 and its two-hundred day moving average price is $7.94. The company has a debt-to-equity ratio of 26.29, a current ratio of 0.22 and a quick ratio of 0.22.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx's pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company's lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.